Company: IPSC
Filing Date: 2025-12-02
Form Type: DEF 14A
Source: 0001104659-25-117704
Chunk: 9

Company: Century Therapeutics, Inc.
Filing Date: 2025-12-02
Form: DEF 14A
Chunk 9
---
2025. (8) Consists of (i) 5,000 shares of common stock and (ii) options to purchase 127,744 shares of our common stock that can be exercised within 60 days of November 15, 2025. (9) Consists of options to purchase 127,744 shares of our common stock that can be exercised within 60 days of November 15, 2025. (10) Consists of options to purchase 227,227 shares of our common stock that can be exercised within 60 days of November 15, 2025. (11) Consists of options to purchase 147,616 shares of our common stock that can be exercised within 60 days of November 15, 2025. (12) Consists of (i) 26,706 restricted stock units that vest within 60 days of November 15, 2025; and (ii) options to purchase 2,239,421 shares of our common stock that can be exercised within 60 days of November 15, 2025. Notice of Special Meeting of Stockholders and 2025 Proxy Statement | 4

| ​ | ITEMS TO BE VOTED ON | ​ |

PROPOSAL 1: APPROVAL OF AN AMENDMENT TO THE CHARTER TO EFFECT A REVERSE STOCK SPLIT OF OUR OUTSTANDING SHARES OF COMMON STOCK BY A RATIO OF ANY WHOLE NUMBER BETWEEN 1-FOR-5 AND 1-FOR-30, THE IMPLEMENTATION AND TIMING OF WHICH SHALL BE SUBJECT TO THE DISCRETION OF THE BOARD We are seeking stockholder approval to grant the Board discretionary authority to amend the Charter, if at all, to effect a reverse stock split of our outstanding shares of Common Stock, at any time before June 30, 2026, by a ratio of any whole number between 1-for-5 and 1-for-30 (the “Reverse Stock Split”). The Reverse Stock Split will not change the number of authorized shares of Common Stock or the relative voting power of such holders of our outstanding Common Stock. The number of authorized but unissued shares of our Common Stock will materially increase and will be available for reissuance by the Company. The Reverse Stock Split, if effected, would affect all of our stockholders uniformly. The Board unanimously approved, and recommended seeking stockholder approval of the Reverse Stock Split, on November 18, 2025. If this Reverse Stock Split is approved